Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
M Sereno, G Gutiérrez-Gutiérrez, JM Rubio… - BMC cancer, 2017 - Springer
Background Oxaliplatin is a chemotherapy agent active against digestive tumors. Peripheral
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around
60–80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology
of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium
channel (type IX, subunit α) and mutations in this gene are involved in neuropathic
perception. In this study we investigated whether SCN9A genetic variants were associated …
neuropathy is one of the most important dose-limiting toxicity of this drug. It occurs in around
60–80% of the patients, and 15% of them develop severe neuropathy. The pathophysiology
of oxaliplatin neurotoxicity remains unclear. SCN9A is a gene codifying for a subtype sodium
channel (type IX, subunit α) and mutations in this gene are involved in neuropathic
perception. In this study we investigated whether SCN9A genetic variants were associated …
[引用][C] Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
M Sereno-Moyano, G Gutiérrez-Gutiérrez, JM Rubio… - 2017
以上显示的是最相近的搜索结果。 查看全部搜索结果